secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-09-30T20:15:18+00:00
Accession:  0001213900-26-105240
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

MoonLake files FDA BLA for sonelokimab in hidradenitis suppurativa
------------------------------------------------------------------

- BLA submitted September 30, 2026 seeking approval of tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 and older.
- MoonLake expects FDA notice on whether the BLA is accepted for review within roughly 60 days of submission, and the planned review timeline within roughly 74 days.
- Filing discloses no efficacy, safety, pricing or financial data; the 8-K reports only the regulatory submission milestone.
- Risks cited include limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties for trials; signed by CFO Matthias Bodenstedt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026105240/0001213900-26-105240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026105240/ea0307097-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-105240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer